Is Metformin 500 mg an appropriate treatment for hidradenitis suppurativa?

Metformin 500 mg for Hidradenitis Suppurativa

Yes, metformin 500 mg is an appropriate treatment option for hidradenitis suppurativa, particularly in patients with insulin resistance, metabolic syndrome, or polycystic ovarian syndrome, and can be used either as monotherapy for mild-to-moderate disease or as adjunctive therapy for more severe disease. 1, 2

Guideline-Based Recommendations

The most recent 2025 North American guidelines specifically recommend metformin in pediatric patients with HS, especially in cases of insulin resistance 1. The 2019 guidelines state that hormonal agents including metformin should be considered in appropriate female patients, either as monotherapy for mild-to-moderate HS or in combination with other agents for more severe disease 2.

Dosing and Administration

Start with metformin 500 mg twice daily with meals, then titrate up to 500 mg 2-3 times daily based on tolerance and response. 2 The FDA-approved dosing allows for gradual escalation up to 2550 mg daily in divided doses, though most HS studies used 500 mg 2-3 times daily 3.

Patient Selection Criteria

Metformin works best in:

• Female patients (most evidence is in women) 2
• Patients with insulin resistance or polycystic ovarian syndrome features 1, 2
• Patients with metabolic syndrome or obesity (BMI typically elevated in responders) 4
• Patients reporting menstrual cycle-related HS flares 2

Expected Outcomes and Timeline

In the largest prospective study of 25 patients, 72% showed significant improvement in Sartorius score and 64% improved in quality of life (DLQI) after 24 weeks 2. More recent systematic reviews confirm these findings, with response rates around 46-50% 5. Clinical improvement typically requires at least 12-24 weeks of treatment 6.

Mechanism of Action in HS

Metformin works through multiple pathways beyond glucose control:

• Reduces inflammatory cytokines (TNF-α, IL-17, IL-8, IFN-γ) 6, 7
• Suppresses NLRP3 inflammasome activation 7
• Modulates AMPK-mTOR pathway, reducing glycolysis and protein synthesis 7
• Improves cardiovascular risk biomarkers (neutrophil-lymphocyte ratio, monocyte-lymphocyte ratio) 4
• Anti-androgenic effects in appropriate patients 2

Safety Profile

Metformin is well-tolerated with only mild, transient gastrointestinal side effects reported in HS studies 8, 6. No severe or unexpected adverse events have been documented in HS populations 8.

Contraindications and Monitoring

• Contraindicated if eGFR <30 mL/min/1.73 m² 3
• Do not initiate if eGFR 30-45 mL/min/1.73 m² 3
• Assess renal function before starting and periodically thereafter 3
• Discontinue before iodinated contrast procedures in at-risk patients 3

Clinical Integration Strategy

For mild-to-moderate HS:

• Consider metformin as first-line monotherapy in females with metabolic features 2
• Alternative to or in combination with tetracyclines 2

For moderate-to-severe HS:

• Use as adjunctive therapy with systemic antibiotics or biologics 2
• Particularly valuable when addressing metabolic comorbidities simultaneously 4

For pediatric patients:

• Specifically recommended in adolescents with insulin resistance 1
• Consider alongside other anti-androgens like spironolactone in adolescent females 1

Common Pitfalls to Avoid

1. Don't expect rapid results - Allow at least 12-24 weeks before assessing efficacy 6
2. Don't overlook metabolic screening - 77% of HS patients have insulin resistance and 44% have metabolic syndrome; these comorbidities need management regardless of HS response 4
3. Don't use in males without considering alternatives - Most evidence is in females; finasteride may be more appropriate for males 1, 5
4. Don't forget GI side effect counseling - Starting with meals and gradual titration minimizes dropout 8

Evidence Quality Considerations

While the 2025 guidelines provide the most current recommendations 1, the evidence base remains limited with small sample sizes and variable outcome measures 2. The strongest prospective data comes from a 24-week uncontrolled study of 25 patients 2. Recent mechanistic studies from 2023 provide compelling biological rationale for metformin's efficacy through immunometabolic reprogramming 7. The conditional recommendation strength reflects limited but consistent positive evidence with an excellent safety profile 1, 2.